Overview

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 14332 CL following administration of multiple rising oral doses over 10 days in patients with type 2 diabetes.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim